Foresee Pharmaceuticals announces the Casppian Phase 3 Study Meets Primary Efficacy Endpoint, Demonstrating Robust LH Suppression with 6-Month Dosing Interval of leuprolide ...

Foresee Pharmaceuticals (TPEx: 6576), ("Foresee") today announced positive topline results from its Phase 3 Casppian clinical trial evaluating the efficacy and safety of FP-001 42 mg (leuprolide ...

Worked abroad? Here’s what to consider about moving your pension savings to Canada

Many Canadians have built retirement savings outside the country after years spent working in the U.S., the U.K. or elsewhere ...